Skip to main content
Find a DoctorGet Care Now
Skip to main content
Search icon magnifying glass







Eric P. Winer to lead Smilow Cancer Hospital, Yale Cancer Center

winerYale New Haven Health and Yale School of Medicine recently announced Eric P. Winer, MD, as the next physician-in-chief of Smilow Cancer Hospital and director of Yale Cancer Center (YCC), effective Feb. 1, 2022.

An internationally renowned expert in breast cancer, Dr. Winer is currently the Thompson Chair in Breast Cancer Research, chief clinical development officer, and senior vice president for medical affairs at Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School.

“Dr. Winer is a nationally-recognized leader in breast cancer care and research, a much sought-after mentor for younger clinicians and an advocate for his patients,” said Marna P. Borgstrom, CEO, YNHHS. “We are delighted to welcome him to Smilow Cancer Hospital, where he’ll lead a team that shares his passion and commitment to providing exceptional care to cancer patients.”

Dr. Winer is president-elect of the American Society of Clinical Oncology (ASCO) and a member of the Scientific Advisory Board of the Breast Cancer Research Foundation. For over a decade, he served as chief scientific advisor and chair of the Scientific Advisory Board for Susan G. Komen for the Cure. He currently co-leads the National Cancer Institute Breast Cancer Steering Committee. 

He is an alumnus of both Yale College and Yale School of Medicine. After receiving his medical degree in 1983, Dr. Winer completed training in internal medicine, serving as chief resident at Yale New Haven Hospital. He completed a fellowship in hematology/oncology at Duke University School of Medicine and served on the Duke faculty before joining Dana-Farber and Brigham and Women’s Hospital.

“I am thrilled to be returning to Yale,” he said. “As a community, I believe we can become a premier cancer center in the next five years. I look forward to building upon the strong clinical and research programs already in place and to enhancing collaborations between laboratory and clinical investigators.”